SPERO THERAPEUTICS INC

SPRO: Spero Therapeutics secures a $1.1B licensing deal for anti‑CD40L antibody IBI355 and a $105M royalty financing, boosting its IgG4‑RD and Sjögren’s disease pipeline.

Discover how Spero Therapeutics is battling multi‑drug resistant infections with an innovative antibiotic‑boosting platform, driving biotech breakthroughs on Nasdaq.

Spero Therapeutics Inc, a biopharmaceutical company, is working to combat multi-drug resistant bacterial infections, but its financial indicators and market volatility raise questions about its stability and growth potential.

Spero Therapeutics’ stock price surged by over 200% after a clinical trial for its antibiotic treatment, tebipenem HBr, showed promising results and was stopped early due to efficacy.

Spero Therapeutics, a biopharmaceutical company, is pioneering the fight against multi-drug resistant bacterial infections with innovative treatments and a commitment to addressing the urgent need for new antibiotics.